Failure of Terminal Ureagenesis: Metabolic and Clinical Features of Arginase Deficiency

The urea cycle is the primary biochemical pathway by which terrestrial mammals detoxify excess nitrogen generated during amino acid catabolism. Free ammonia (NH₃/NH₄⁺) is highly toxic, particularly to the central nervous system, where it disrupts neurotransmission, cerebral energy metabolism, and osmotic balance. To prevent these effects, hepatocytes convert nitrogen into urea through a five-step cyclic process that spans two cellular compartments: the mitochondrial matrix and the cytosol. Nitrogen moves through the pathway as ornithine → citrulline → arginino-succinate → arginine → ornithine, with each step catalyzed by a specific enzyme (Figure 1). The final step of this cycle is uniquely catalyzed by arginase, a cytosolic, manganese-dependent hydrolase that converts arginine into urea and ornithine (Scheme1). Regeneration of ornithine is essential, as it allows continued cycling of intermediates and maintains overall urea-cycle flux. 

Scheme.1 Arginase-catalyzed hydrolysis of L-arginine (1) to urea (3) and ornithine (4).

Figure.1 The urea cycle and its metabolic connections to amino acid catabolism and gluconeogenesis. (Voet, 2013) 

Argininemia (Arginase-1 deficiency), also known as hyperargininemia, is a rare autosomal recessive inborn error of metabolism caused by pathogenic variants in the ARG1 gene located on chromosome 6q23.2. In healthy individuals, arginase-1 functions as a homotrimer, and proper folding as well as manganese binding at the active site are required for catalytic activity. In affected individuals, biallelic mutations—including missense, nonsense, frameshift, and splice-site variants—reduce enzyme activity to less than 1% of normal (Diez-Fernandez et al., 2018). Many missense mutations destabilize α-helical regions near the active site or interfere with metal coordination, while truncating mutations prevent proper trimer formation and render the enzyme nonfunctional (Sun et al., 2020). Because arginase-1 catalyzes the terminal step of the urea cycle, impairment of this enzyme prevents efficient hydrolysis of arginine into urea, directly limiting nitrogen excretion. 

Unlike proximal urea-cycle disorders, upstream enzymes such as carbamoyl phosphate synthetase I, ornithine transcarbamylase, and argininosuccinate lyase remain functional in arginase deficiency (Figure 1). This allows partial buffering of nitrogen through continued synthesis of citrulline and argininosuccinate, delaying severe hyperammonemia in infancy. However, failure to regenerate ornithine slows overall cycle throughput, and arginine accumulates progressively in the plasma to levels three- to four-fold above normal. In addition, arginine is metabolized into guanidino compounds, including guanidinoacetate, which are neurotoxic and contribute to disease pathology (De Deyn et al., 1997). The resulting biochemical profile is characterized by marked hyperargininemia with variable but clinically significant hyperammonemia. 

Clinically, individuals with arginase-1 deficiency often appear developmentally normal during early infancy, but symptoms typically emerge between one and three years of age. One of the most distinctive features of the disorder is progressive spastic diplegia, predominantly affecting the lower extremities. This presentation frequently leads to misdiagnosis as cerebral palsy before metabolic testing reveals the underlying cause (Huemer et al., 2016). From a biochemical perspective, neurological deterioration reflects the combined effects of chronic hyperargininemia, accumulation of arginine-derived guanidino metabolites, and episodic hyperammonemia. These metabolites interfere with inhibitory neurotransmission, promote excitotoxicity, and disrupt astrocyte osmotic regulation, ultimately impairing cortical and motor neuron function. 

Because arginase-1 is expressed primarily in hepatocytes, the liver is the central site of metabolic dysfunction in this disorder. Impaired ureagenesis leads to inefficient nitrogen clearance and contributes to persistent elevations in circulating arginine and ammonia. Although severe hepatic failure is uncommon, chronic metabolic stress may result in mild hepatomegaly, elevated transaminases, and altered hepatic amino acid handling, particularly during periods of increased catabolism. In parallel, the kidneys assume an increased compensatory role in nitrogen excretion. Elevated plasma arginine increases renal filtration and urinary excretion of amino acids, sometimes producing aminoaciduria and reducing the kidney’s ability to concentrate urine effectively. This renal burden can exacerbate dehydration during illness and further destabilize metabolic control. Over time, affected individuals may experience developmental delay, seizures, loss of motor milestones, and cognitive impairment, reflecting the combined impact of neurological toxicity and chronic hepatic and renal metabolic stress. 

Living with arginase-1 deficiency requires lifelong metabolic management focused on minimizing nitrogen load while supporting normal growth and development. Because dietary protein intake directly contributes to arginine and ammonia production, individuals must adhere to a carefully regulated low-protein diet. Specialized arginine-free essential amino acid formulas provide necessary substrates for protein synthesis without exacerbating metabolic toxicity. During periods of illness or fasting, increased protein catabolism can rapidly overwhelm the compromised urea cycle, necessitating increased carbohydrate intake to suppress endogenous proteolysis. Regular biochemical monitoring of plasma ammonia, amino acids, and liver function markers is essential, particularly during early childhood when neurological injury is most likely to occur. 

Pharmacologic treatment of arginase-1 deficiency is centered on reducing systemic nitrogen burden by bypassing the impaired urea cycle altogether. Nitrogen-scavenging agents such as sodium benzoate and sodium phenylbutyrate provide alternative biochemical routes for nitrogen disposal that do not rely on arginase activity. Sodium benzoate conjugates with glycine to form hippurate, which is readily excreted by the kidneys, thereby removing one nitrogen atom per molecule excreted. Sodium phenylbutyrate is metabolized via β-oxidation to phenylacetate, which conjugates with glutamine to form phenylacetylglutamine, allowing removal of two nitrogen atoms per molecule. These reactions effectively substitute for urea formation and lower plasma ammonia levels independently of ureagenesis, making them central to both acute and long-term management of the disorder (Diez-Fernandez et al., 2018). 

In addition to pharmacologic scavenging, patients require strict dietary management to limit arginine and total nitrogen intake. Low-protein diets supplemented with arginine-free essential amino acid formulas reduce substrate flow into the defective pathway while still supporting growth and tissue maintenance. During periods of illness or metabolic stress, intravenous dextrose is often administered to suppress endogenous protein catabolism and prevent hyperammonemic crises. In severe or refractory cases, liver transplantation provides a definitive metabolic cure by replacing deficient hepatocytes with cells expressing functional arginase-1. Post-transplantation, plasma arginine and ammonia levels normalize rapidly; however, neurological deficits acquired prior to transplantation often persist, highlighting the importance of early metabolic control (Gomes Martins et al., 2010). 

Overall, arginase-1 deficiency illustrates how disruption of a single enzymatic reaction (Scheme 1) can destabilize an entire metabolic pathway (Figure 1). The urea cycle normally converts toxic ammonia into inert urea, safeguarding neurological function and nitrogen homeostasis. When this terminal step fails, nitrogen accumulates in biochemically predictable but clinically devastating ways, underscoring the tight coupling between enzyme function, metabolic flux, and human disease. 

References: 

Bharathi, S. S., Sravani, S., Reddy, N. K., & Reddy, B. M. (2022). Phenotypic pleiotropy in arginase deficiency. Annals of Indian Academy of Neurology, 25(5), 871–876. https://doi.org/10.4103/aian.aian_1042_21 

Cantero, G., et al. (2016). Gene therapy approaches for urea cycle disorders: Progress and challenges. Molecular Genetics and Metabolism, 117(2), 128–137. https://doi.org/10.1016/j.ymgme.2015.11.010 

Cederbaum, S. D., Shaw, K. N. F., Spector, E. B., Verity, M. A., Snodgrass, P. J., & Sugarman, G. I. (1979). Hyperargininemia with arginase deficiency. Pediatric Research, 13(8), 827–833. https://doi.org/10.1203/00006450-197908000-00002 

De Deyn, P. P., D’Hooge, R., Van Bogaert, P. P., & Marescau, B. (1997). Endogenous guanidino compounds as uremic neurotoxins. Kidney International, 52(S62), S77–S83. 

Diez-Fernandez, C., et al. (2018). Molecular and phenotypic spectrum of arginase 1 deficiency. Journal of Inherited Metabolic Disease, 41(5), 795–804. https://doi.org/10.1007/s10545-018-0202-9 

Gomes Martins, E., et al. (2010). Liver transplantation in urea cycle disorders: A systematic review. Pediatric Transplantation, 14(8), 1061–1069. https://doi.org/10.1111/j.1399-3046.2010.01371.x 

Hewson, S., Clarke, J. T. R., & Cederbaum, S. D. (2003). Prenatal diagnosis for arginase deficiency: A case study. Journal of Inherited Metabolic Disease, 26(6), 607–610. https://doi.org/10.1023/A:1025154321956 

Huemer, M., et al. (2016). Clinical presentation, diagnosis, and management of arginase deficiency. Orphanet Journal of Rare Diseases, 11, Article 128. https://doi.org/10.1186/s13023-016-0508-9 

Lee, E. K., et al. (2016). Recombinant arginase therapy for arginase deficiency. Molecular Genetics and Metabolism, 118(4), 271–277. https://doi.org/10.1016/j.ymgme.2016.06.006 

Pavuluri, S., et al. (2023). Arginase deficiency: An unheralded cause of developmental epileptic encephalopathy. Epileptic Disorders, 25(1), 38–46. https://doi.org/10.1684/epd.202 

Voet, D., Voet, J. G., & Pratt, C. W. (2013). Fundamentals of biochemistry: Life at the molecular level (4th ed., p. 724). Wiley. 

Assessed and Endorsed by the MedReport Medical Review Board